-
Something wrong with this record ?
Nivolumab induced encephalopathy in a man with metastatic renal cell cancer: a case report
J. Kopecký, O. Kubeček, T. Geryk, B. Slováčková, P. Hoffmann, M. Žiaran, P. Priester,
Language English Country England, Great Britain
Document type Case Reports, Journal Article
NLK
BioMedCentral
from 2007-12-01
BioMedCentral Open Access
from 2007
Directory of Open Access Journals
from 2007
Free Medical Journals
from 2007
PubMed Central
from 2007
Europe PubMed Central
from 2007
ProQuest Central
from 2015-01-01
Open Access Digital Library
from 2007-01-01
Nursing & Allied Health Database (ProQuest)
from 2015-01-01
Health & Medicine (ProQuest)
from 2015-01-01
Health Management Database (ProQuest)
from 2015-01-01
Public Health Database (ProQuest)
from 2015-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2007
Springer Nature OA/Free Journals
from 2007-12-01
- MeSH
- Encephalitis chemically induced MeSH
- Carcinoma, Renal Cell drug therapy secondary MeSH
- Middle Aged MeSH
- Humans MeSH
- Kidney Neoplasms drug therapy pathology MeSH
- Nivolumab adverse effects MeSH
- Antineoplastic Agents, Immunological adverse effects MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Publication type
- Journal Article MeSH
- Case Reports MeSH
BACKGROUND: Great progress has recently been made in the treatment of metastatic renal cell carcinoma, including the introduction of nivolumab, an immune checkpoint inhibitor. Despite promising results, this treatment brings a completely new spectrum of adverse events, distinct from those experienced with small-molecule kinase inhibitors. Neurologic immune-related adverse events may be serious and potentially life-threatening complications requiring immediate immunosuppressive therapy. Only a few cases of immune-related encephalitis induced by checkpoint inhibitors have been described and the data regarding the management of this serious adverse event are limited. CASE PRESENTATION: We report the case of a 63-year-old white man with metastatic renal cancer who developed severe chorea-like dyskinesia during nivolumab therapy. The findings on brain magnetic resonance imaging and flow cytometry of cerebrospinal fluid, and the positivity of anti-paraneoplastic antigen Ma2 immunoglobuline G class autoantibodies were consistent with a diagnosis of immune-related encephalitis. High-dose intravenous corticosteroid therapy was started immediately, with no signs of improvement, even when infliximab was added. Our patient refused further hospitalization and was discharged. Three weeks later, he presented with signs of severe urosepsis. Despite intensive treatment, he died 4 days after admission. CONCLUSIONS: The management of less frequent immune-related adverse events has not been fully established and more information is required to provide uniform recommendations. Immune-related encephalitis is a severe and potentially fatal complication requiring immediate hospital admission and extensive immunosuppressive therapy. The examination of cerebrospinal fluid for paraneoplastic antibodies, such as anti-N-methyl-D-aspartate receptor and anti-Ma2 antibodies, in order to distinguish autoimmune etiology from other possible causes is essential and highly recommended.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19012378
- 003
- CZ-PrNML
- 005
- 20190425105048.0
- 007
- ta
- 008
- 190405s2018 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1186/s13256-018-1786-9 $2 doi
- 035 __
- $a (PubMed)30217214
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Kopecký, Jindřich $u Department of Clinical Oncology and Radiotherapy, University Hospital in Hradec Králové, Sokolská 581, 50005, Hradec Králové, Czech Republic. kopecjin@fnhk.cz.
- 245 10
- $a Nivolumab induced encephalopathy in a man with metastatic renal cell cancer: a case report / $c J. Kopecký, O. Kubeček, T. Geryk, B. Slováčková, P. Hoffmann, M. Žiaran, P. Priester,
- 520 9_
- $a BACKGROUND: Great progress has recently been made in the treatment of metastatic renal cell carcinoma, including the introduction of nivolumab, an immune checkpoint inhibitor. Despite promising results, this treatment brings a completely new spectrum of adverse events, distinct from those experienced with small-molecule kinase inhibitors. Neurologic immune-related adverse events may be serious and potentially life-threatening complications requiring immediate immunosuppressive therapy. Only a few cases of immune-related encephalitis induced by checkpoint inhibitors have been described and the data regarding the management of this serious adverse event are limited. CASE PRESENTATION: We report the case of a 63-year-old white man with metastatic renal cancer who developed severe chorea-like dyskinesia during nivolumab therapy. The findings on brain magnetic resonance imaging and flow cytometry of cerebrospinal fluid, and the positivity of anti-paraneoplastic antigen Ma2 immunoglobuline G class autoantibodies were consistent with a diagnosis of immune-related encephalitis. High-dose intravenous corticosteroid therapy was started immediately, with no signs of improvement, even when infliximab was added. Our patient refused further hospitalization and was discharged. Three weeks later, he presented with signs of severe urosepsis. Despite intensive treatment, he died 4 days after admission. CONCLUSIONS: The management of less frequent immune-related adverse events has not been fully established and more information is required to provide uniform recommendations. Immune-related encephalitis is a severe and potentially fatal complication requiring immediate hospital admission and extensive immunosuppressive therapy. The examination of cerebrospinal fluid for paraneoplastic antibodies, such as anti-N-methyl-D-aspartate receptor and anti-Ma2 antibodies, in order to distinguish autoimmune etiology from other possible causes is essential and highly recommended.
- 650 _2
- $a protinádorové látky imunologicky aktivní $x škodlivé účinky $7 D000074322
- 650 _2
- $a karcinom z renálních buněk $x farmakoterapie $x sekundární $7 D002292
- 650 _2
- $a encefalitida $x chemicky indukované $7 D004660
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a nádory ledvin $x farmakoterapie $x patologie $7 D007680
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a nivolumab $x škodlivé účinky $7 D000077594
- 655 _2
- $a kazuistiky $7 D002363
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Kubeček, Ondřej $u Department of Clinical Oncology and Radiotherapy, University Hospital in Hradec Králové, Sokolská 581, 50005, Hradec Králové, Czech Republic.
- 700 1_
- $a Geryk, Tomáš $7 xx0235124 $u Department of Fingerland Pathology, University Hospital in Hradec Králové, Sokolská 581, 50005, Hradec Králové, Czech Republic.
- 700 1_
- $a Slováčková, Birgita $u Department of Psychiatry, University Hospital in Hradec Králové, Sokolská 581, 50005, Hradec Králové, Czech Republic.
- 700 1_
- $a Hoffmann, Petr $u Department of Radiology, University Hospital in Hradec Králové, Sokolská 581, 50005, Hradec Králové, Czech Republic.
- 700 1_
- $a Žiaran, Miroslav $7 xx0235093 $u Department of Clinical Oncology and Radiotherapy, University Hospital in Hradec Králové, Sokolská 581, 50005, Hradec Králové, Czech Republic.
- 700 1_
- $a Priester, Peter $u Department of Clinical Oncology and Radiotherapy, University Hospital in Hradec Králové, Sokolská 581, 50005, Hradec Králové, Czech Republic.
- 773 0_
- $w MED00184060 $t Journal of medical case reports $x 1752-1947 $g Roč. 12, č. 1 (2018), s. 262
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30217214 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190405 $b ABA008
- 991 __
- $a 20190425105128 $b ABA008
- 999 __
- $a ok $b bmc $g 1391688 $s 1050683
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 12 $c 1 $d 262 $e 20180915 $i 1752-1947 $m Journal of medical case reports $n J Med Case Reports $x MED00184060
- LZP __
- $a Pubmed-20190405